Format

Send to

Choose Destination
See comment in PubMed Commons below
Transpl Infect Dis. 2009 Jun;11(3):195-202. doi: 10.1111/j.1399-3062.2009.00372.x. Epub 2009 Feb 18.

Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation.

Author information

1
VCU Department of Surgery, Division of Transplantation Surgery, Virginia Commonwealth University, Richmond, Virginia 23298, USA. rafisher@vcu.edu

Abstract

As the most prevalent pathogen among transplant patients, cytomegalovirus (CMV) affects up to three-quarters of all solid organ transplant recipients. While we have made great strides in preventing CMV infection and disease in the early post-transplant period, late CMV infection and indirect effects due to viral immunomodulation remain problematic. Changing immunosuppression practices, including the increasing use of T-cell depleting induction antibodies, have the potential to affect the risk for CMV infection and disease, even in the face of good prophylactic and preemptive therapy. The purpose of this review article is to discuss the impact of CMV infection on long-term allograft outcomes and to re-evaluate the risks and management strategies for prevention of CMV in the framework of evolving modern immunosuppressive strategies.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center